论文部分内容阅读
目的探讨奥拉西坦治疗脑梗死恢复期患者轻度认知障碍的临床疗效。方法选取2014年3月—2015年4月盐城市第三人民医院收治的脑梗死恢复期患者80例,根据就诊顺序分为对照组和观察组,各40例。对照组患者采用常规治疗,观察组患者在常规治疗基础上加用奥拉西坦,两组患者治疗时间均为6周。比较两组患者临床疗效及治疗前后简明精神症状检查表(MMSE)评分、巴氏指数(BI)评分。结果观察组患者临床疗效优于对照组(Z=5.541,P<0.05)。治疗前两组患者MMSE评分和BI评分比较,差异无统计学意义(P>0.05);治疗后观察组患者MMSE评分和BI评分高于对照组(P<0.05)。治疗后两组患者MMSE评分和BI评分均高于治疗前(P<0.05)。结论奥拉西坦治疗脑梗死恢复期患者轻度认知功能障碍的临床疗效确切,可有效改善患者精神状况和日常生活能力。
Objective To investigate the clinical efficacy of oxiracetam in the treatment of mild cognitive impairment in patients with convalescent cerebral infarction. Methods From March 2014 to April 2015, 80 patients with convalescence of cerebral infarction treated in Yancheng Third People ’s Hospital were enrolled. According to the order of treatment, they were divided into control group and observation group, 40 cases each. Patients in the control group were treated with conventional therapy. Patients in the observation group were given oxiracetam on the basis of conventional treatment. Both groups were treated for 6 weeks. The curative effect of both groups were compared before and after treatment with MMSE and BI scores. Results The clinical efficacy of the observation group was better than that of the control group (Z = 5.541, P <0.05). There was no significant difference in MMSE score and BI score between the two groups before treatment (P> 0.05). MMSE score and BI score in the observation group were higher than those in the control group after treatment (P <0.05). MMSE score and BI score of two groups after treatment were higher than before treatment (P <0.05). Conclusion Oxiracetam is effective in treating mild cognitive impairment in patients with convalescent cerebral infarction, which can effectively improve the mental status and daily living ability of patients.